CN105349474A - Lactobacillus.crispatus for preventing female urogenital tract infection - Google Patents
Lactobacillus.crispatus for preventing female urogenital tract infection Download PDFInfo
- Publication number
- CN105349474A CN105349474A CN201510954618.6A CN201510954618A CN105349474A CN 105349474 A CN105349474 A CN 105349474A CN 201510954618 A CN201510954618 A CN 201510954618A CN 105349474 A CN105349474 A CN 105349474A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- crispatus
- bacterium
- imc
- lactobacillus curvatus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
Abstract
The invention discloses lactobacillus.crispatus for preventing female urogenital tract infection. The lactobacillus.crispatus specifically refers to lactobacillus.crispatus IMC-25. The lactobacillus.crispatus IMC-25 has higher anti-bacterial capacity, can effectively inhibit growth of extraneous pathogenic bacteria and other conditioned pathogens, also has higher adhesive function on vaginal epithelial cells and guarantees colonization of strains on vaginal epitheliums. The lactobacillus.crispatus IMC-25 has certain application prospect in the aspect of prevention of urogenital tract infection.
Description
Technical field
The invention belongs to biological technical field, relate to lactobacillus curvatus and application thereof, particularly for preventing and treating the lactobacillus curvatus of women's urogenital infections.
Background technology
Urogenital infections has a strong impact on the able-bodied common disease of numerous women, and be mostly intestinal bacteria or infection of staphylococcus aureus, morbidity is up to 40%; Its treatment mainly relies on microbiotic, but curative ratio is on the low side, and recurrence rate can reach more than 40%.
In order to reduce the recurrence rate of urogenital infections, be badly in need of new treatment plan clinically.Due to the toxic side effect such as liver, renal impairment that antibiotic therapy urogenital infections less effective and antibiotic therapy cause, making great efforts both at home and abroad to explore the Tiny ecosystem therapy based on probiotic Lactobacillus preparation always.Microecologic cure to be that main methods for the treatment of becomes the novel therapeutic theory increased for the purpose of probiotic bacterium, the normal micro-ecological environment of recovery vagina by killing microorganisms.Namely after utilizing microbiotic to remove pathogenic bacterium, directly supplement the living preparation of lactobacillus preparation be separated from healthy women vagina, its Colonization is got off, the ability of the opposing pathogenic bacterium growth promoting it natural.
One is improved and effective probiotic bacterium bacterial classification, and itself at least must possess following standard: (1) must be the normal field planting bacterium of host's application site; (2) can survive in host's application site and grow; (3) host can be provided useful effect; (4) related products is made and must can be maintained active and survival ability between the shelf lives.
At present, state's per vaginam probiotics bacterial agent only has one, and its main component is lactobacillus delbruckii viable bacteria.Although it is a kind of Bacterium lacticum separated from healthy women vagina, the normal definite value bacterium in Bu Shi China woman vagina flora.
Can there is various bacteria in woman vagina, wherein, lactobacillus maintains the most common and most important probiotics of vaginal health micro-ecological environment, and lactobacillus accounts for more than 90% of healthy women vaginal bacteria total amount.They are mainly through the growth of producing acid, hydrogen peroxide suppresses pathogenic bacteria and other conditioned pathogens.If some factor causes intravaginal Bacterium lacticum quantity to reduce, lack even completely, then the many conditions of intravaginal can be caused to cure the disease bacterium abnormality proliferation, and travel to urethra and cause urogenital infections.
There is multiple Bacterium lacticum in healthy women intravaginal; recent research confirms that the dominant strain in healthy women vaginal microbial flora with provide protection is lactobacillus curvatus; between each strain of lactobacillus curvatus, anti-pathogenic bacterium capacity variance is obvious; there is individual difference; therefore; when selecting Bacterium lacticum probiotic bacterium; need the kind considering Bacterium lacticum; it produces acid, bacteriostasis; and the ability to adhere to vaginal epithelial cell; wherein can lactobacillus in vagina success field planting, and being the basis of Bacterium lacticum continuous action, is also the key factor that Bacterium lacticum plays curative effect.
Because different lactobacillus curvatus strains has different adhesion avidity to vaginal epithelial cell, the bacterial strain colonization ability that avidity is strong is strong, but just can play the effect of killing multiple pathogenic microorganisms.If living preparation of lactobacillus preparation can not field planting at vaginal epithelial cell, but the effect of killing multiple pathogenic microorganisms strong again in experiment in vitro is not all known where to begin, and becomes kite bill.
From healthy women vagina, be separated over one hundred strain lactobacillus curvatus, and therefrom filter out can efficient antagonism female genital pathogenic bacterium, there is with vaginal epithelial cell again the bacterial strain of higher adhesive capacity; As with these preferred bacterial strain development lactobacillus goods, the deficiency of gynaecology's lactobacillus goods of current Clinical practice will be overcome, improve the result for the treatment of of women's urogenital infections.
Consider the effect of the strengthening vital QI to eliminate pathogenic factors of the urogenital infections patient groups that China is huge and vagina advantage Bacterium lacticum, the market outlook that gynaecology develops with Lemonal are extremely bright.
Summary of the invention
An object of the present invention is to provide strain lactobacillus curvatus (Lactobacillus.crispatus) IMC-25.
Strain lactobacillus curvatus (Lactobacillus.crispatus) IMC-25, its preserving number CGMCCNO.11344 provided by the invention.
Above-mentioned lactobacillus curvatus or its tunning or its bacteria suspension or its nutrient solution are also the scope of protection of the invention in the preparation application prevented and/or treated in urogenital infections product.
Above-mentioned lactobacillus curvatus or its tunning or its bacteria suspension or its nutrient solution are also the scope of protection of the invention preparing the application in antimicrobial product.
In above-mentioned application, described bacterium is bacterium, and described bacterium is specially streptococcus aureus.
The application that above-mentioned lactobacillus curvatus or its tunning or its bacteria suspension or its nutrient solution adhere in vaginal epithelial cell product in preparation is also the scope of protection of the invention.
Another object of the present invention is to provide one and prevents and/or treats urogenital infections product.
Product provided by the invention, its activeconstituents is above-mentioned lactobacillus curvatus or its tunning or its bacteria suspension or its nutrient solution.
The present invention's the 3rd object is to provide a kind of antimicrobial product.
Antimicrobial product provided by the invention, its activeconstituents is above-mentioned lactobacillus curvatus or its tunning or its bacteria suspension or its nutrient solution.
In the said products, described bacterium is bacterium, and described bacterium is specially streptococcus aureus.
The present invention's the 4th object is to provide a kind of adhesion vaginal epithelial cell product.
Product provided by the invention, its activeconstituents is above-mentioned lactobacillus curvatus or its tunning or its bacteria suspension or its nutrient solution.
The said products is medicine or microbial inoculum.
IMC-25 was on September 9th, 2015, be preserved in China Committee for Culture Collection of Microorganisms's common micro-organisms center and (be called for short CGMCC, address is: No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City), deposit number is CGMCCNO.11344, and Classification And Nomenclature is lactobacillus curvatus (Lactobacillus.crispatus).
The present invention is according to the recognised standard of probiotic bacterium bacterial classification, from intravaginal dominant microflora-lactobacillus curvatus in China's healthy women body, and therefrom filter out a strain there is higher bacteriostasis and probiotic strain-lactobacillus curvatus (Lactobacillus.crispatus) IMC-25 strong with vaginal epithelial cell Colonization ability.Experiment proves, by described lactobacillus curvatus (Lactobacillus.crispatus) IMC-25, according to 10
6the density of cfu/ml is inoculated in MRS liquid nutrient medium, and under anaerobic environment, the fermented liquid of 37 DEG C of quiescent culture 21h, effectively can suppress the growth of the pathogenic bacterium such as streptococcus aureus; The adhesive attraction stronger to vaginal epithelial cell ensure that the field planting of bacterial strain at vagina epithelium.
Accompanying drawing explanation
Fig. 1 is the growth that lactobacillus curvatus (Lactobacillus.crispatus) IMC-25 be separated from Healthy People vagina suppresses Staphylococcus aureus.
Fig. 2 is the adhesive attraction of lactobacillus curvatus (Lactobacillus.crispatus) IMC-25 and vaginal epithelial cell.
Embodiment
The experimental technique used in following embodiment if no special instructions, is ordinary method.
Material used in following embodiment, reagent etc., if no special instructions, all can obtain from commercial channels.
The separation andpreconcentration of embodiment 1, lactobacillus curvatus bacterial strain
One, the separation of lactobacillus curvatus bacterial strain
MRS substratum: peptone 10.0g; Extractum carnis 10.0g; Yeast extract paste 5.0g; Diammonium hydrogen citrate 2.0g; Glucose 20.0g; Tween 80,1.0mL; Sodium acetate (CH
3cOONa3H
2o) 5.0g; Dipotassium hydrogen phosphate (K
2hPO43H
2o) 2.0g; Magnesium sulfate (MgSO
47H
2o) 0.58g; Manganous sulfate (MnSO
4h
2o) 0.25g; Distilled water 1000mL; Be adjusted to pH6.2 ~ 6.6.
Have collected the healthy women vaginal secretion matter sample of the scorching symptom and sign of more than 200 routine clinical detection absence of vagina, by sample number consecutively, be inoculated in MRS liquid nutrient medium, 37 DEG C of Anaerobic culturel 24h.Each sample random choose 5 single bacterium colonies are cultivated and are increased bacterium 24h in 2mLMRS liquid nutrient medium, and to bacterium colony number consecutively.Amplification bacterium is used for bacterium conservation and prepared by DNA.The hundreds of strain bacteriums be separated to are carried out respectively strain identification, suppress Staphylococcus aureus growth and with the detection of vaginal epithelial cell adhesive attraction, a wherein strain is had stronger adhesive attraction and effectively suppresses the lactobacillus curvatus called after IMC-25 of the growth of Staphylococcus aureus.
Two, the qualification of lactobacillus curvatus bacterial strain
1, Morphological Identification
On MRS lactobacillus culture medium flat plate, above-mentioned steps one is separated the bacterial strain IMC-25 obtained and shows as the oyster white bacterium colony that size is about 1-2 millimeter, opaque, projection, and colony edge neatly, more moistening, size and form is stablized.
2, analysis of physio biochemical characteristics
Bacterial strain IMC-25 amphimicrobian, growth optimum temperuture 37-42 DEG C, optimal pH 5.8-6.2.API50CHL substratum and API50CH reagent strip (bioMe ' rieux is utilized according to API Bacteria Identification standard, Inc., Marcyl ' Etoile, France) carry out to detecting bacterial strain IMJ-1 the physiological and biochemical property that sugar-fermenting reaction interpretation detects bacterial strain IMC-25.The simple culture medium that API50CHL is made up of the API50CH test bar of 49 kinds of fermentable carbohydrates.To measure each tubule that bacterium makes suspension inoculation test bar.When cultivating, because fermentable carbohydrates produces acid, pH declines, and makes indicator discoloration.
Result shows, and bacterial strain IMC-25 can the multiple sugar such as glucose fermentation, fructose, sucrose, trehalose, maltose.
3,16srDNA sequence homology analysis
Ordinary method is cultivated above-mentioned steps one and is separated the bacterial strain IMC-25 obtained, extract the STb gene of bacterial strain as gene amplification template, adopt universal primer 27f:5 '-AGAGTTTGATCCTGGCTCAG-3 ', 1492r:5 '-TACGGTTACCTTGTTACGACTT-3 ' amplification bacteria 16 S rRNA genes conserved regions.25 μ L amplification systems comprise: 1 × PCR reaction buffer, 200 μm of ol/LdNTPs, upstream and each 0.2 μm of ol/L, the 1UTaqDNA polysaccharase of downstream primer, 1 μ L template DNA.Reaction conditions: 94 DEG C of denaturation 5min; 94 DEG C of sex change 30s, 55 DEG C of annealing 40s, 72 DEG C extend 30s, totally 25 circulations; 72 DEG C extend 10min.PCR primer 1% detected through gel electrophoresis, positive findings 27f:5 '-AGAGTTTGATCCTGGCTCAG-3 ', 1492r:5 '-TACGGTTACCTTGTTACGACTT-3 ' carries out two-way order-checking.Sequence assembly and similarity analysis use DNAStar software to complete, and sequence alignment is completed online by American National Biotechnology Information center ncbi database (http://www.ncbi.nlm.nih.gov).
The sequence of the 16srDNA of bacterial strain IMC-25 refers to sequence 1 in sequence table.
Through above-mentioned qualification, IMC-25 was on September 9th, 2015, be preserved in China Committee for Culture Collection of Microorganisms's common micro-organisms center and (be called for short CGMCC, address is: No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City), deposit number is CGMCCNO.11344, and Classification And Nomenclature is lactobacillus curvatus (Lactobacillus.crispatus).
The functional analysis of embodiment 2, lactobacillus curvatus (Lactobacillus.crispatus) IMC-25
1, lactobacillus curvatus (Lactobacillus.crispatus) IMC-25 antibacterial ability detects
The IMC-25 Bacterium lacticum of activation incubated overnight to be inoculated in respectively in 10mLMRS liquid nutrient medium and to be placed in 37 DEG C cultivate 16h in the ratio of 10%, and then in 37 DEG C, 3h cultivated by 220r/min shaking table, be stored in after filtering fermentation liquor is degerming 4 DEG C for subsequent use.
Getting 100 μ L after streptococcus aureus (StaphylococcusaureusCGMCC1.1361) (OD600=0.208) 100 times dilution is spread evenly across on MRS solid plate for subsequent use in 4 DEG C.Bacteriostatic activity detects: the fermented liquid getting 250 μ L filtration sterilizations adds in the Oxford cup being placed on and scribbling on indicator flat board respectively, 37 DEG C, incubated overnight in 5%CO2 incubator.
Antifungal composition: organic acid bacteriostatic action detects, fermented liquid Proteinase K (final concentration 0.1g/L) and catalase (final concentration 0.5g/L) process of filtration sterilization.H2O2 bacteriostatic action detects, and neutralise broth pH (pH6.3) also processes with Proteinase K (final concentration 0.1g/L).Bacteriocin sample mixture bacteriostatic action detects, and neutralise broth pH (pH6.3) also processes with catalase (final concentration 0.5g/L).The fermented liquid handled well is respectively got 250 μ L and add the Oxford cup being placed in and scribbling on indicator flat board respectively, be placed in 37 DEG C, 5%CO2 incubator incubated overnight, observe and take a picture.
Bacteriostatic experiment result shows that IMC-25 Bacterium lacticum has very strong restraining effect to streptococcus aureus, is greater than 15 millimeters to the antibacterial circle diameter of S. aureus L-forms, has stronger bacteriostasis (Fig. 1).After lactobacillus ferment liquid Proteinase K and hydrogen peroxide ferment treatment, only retain organic acidic substances, the fungistatic effect of its fungistatic effect and Preliminary fermentation liquid is slightly weak, and do not use Proteinase K and hydrogen peroxide ferment treatment, when only adjusting fermented liquid pH, lactobacillus ferment liquid is to S. aureus L-forms without bacteriostatic action, shows that IMC-25 Bacterium lacticum suppresses the main component of S. aureus L-forms growth to be organic acid.
2, lactobacillus curvatus is to the adhesive attraction of vaginal epithelial cell
Vagina epithelium cast-off cells are taken from more than 20 examples healthy (clinical detection display non-reproductive system infects) Women of Childbearing Age, MEM substratum (pH4.0) is added respectively after each cell sample label, centrifugal 10 minutes of 120g, repeated centrifugation 2 times again, washing surface bacteria off, is 10 by MEM substratum adjustment vagina epithelium cast-off cells concentration
5individual/mL; Activation incubated overnight lactobacillus curvatus (Lactobacillus.crispatus) IMC-25CGMCCNo.11344 makes its concentration be (10
8cFU/mL).Vagina epithelium cast-off cells mix with each 500 μ L equal-volumes of described lactobacillus curvatus (Lactobacillus.crispatus) IMC-25 and are placed on 37 DEG C of shaking tables (rotating speed is 100r/min, rotation radius is 2.54cm) hatch 1h, then 0.8 μm of membrane filtration is used, remove free lactobacillus curvatus (Lactobacillus.crispatus) IMC-25, and filter membrane is gently pressed on cover glass, fixed cell is oily sem observation after carrying out gramstaining, count three cell adhesion bacterial counts respectively, calculate each cell average adhesion bacterial count.
Adopt the method isolation identification of embodiment 1 to obtain equally an other strain, but the lactobacillus curvatus (Lactobacillus.crispatus) more weak with vaginal epithelial cell Colonization power contrast as negative simultaneously.
Result shows, and lactobacillus curvatus (Lactobacillus.crispatus) IMC-25 all has stronger adhesive attraction to separation from the vaginal epithelial cell of more than 20 routine healthy Women of Childbearing Ages.Fig. 2 figure is left for being located away from the vagina epithelium cast-off cells of healthy Women of Childbearing Age; The figure right side is vagina epithelium cast-off cells and lactobacillus curvatus (Lactobacillus.crispatus) IMC-25) stronger adhesive attraction.From more than 20 examples, random selecting 4 example, carry out statistical study, the quantity calculating each vaginal epithelial cell average adhesion lactobacillus curvatus (Lactobacillus.crispatus) IMC-25 reaches 75.
Table 2 vaginal epithelial cell adheres to the quantity statistics of lactobacillus curvatus (Lactobacillus.crispatus) IMC-25
The result of integrated embodiment 1 and embodiment 2, lactobacillus curvatus of the present invention (Lactobacillus.crispatus) IMC-25 had both had stronger antibacterial ability (effectively can suppress the growth of pathogenic bacteria and other conditioned pathogens), have again the stronger adhesive attraction to vaginal epithelial cell (ensure that the field planting of bacterial strain at vagina epithelium), this just makes lactobacillus curvatus (Lactobacillus.crispatus) IMC-25 become candidate's probiotic strain of effectively control urogenital infections.
Claims (10)
1. strain lactobacillus curvatus (Lactobacillus.crispatus) IMC-25, its preserving number CGMCCNO.11344.
2. lactobacillus curvatus according to claim 1 or its tunning or its bacteria suspension or its nutrient solution are preparing the application prevented and/or treated in urogenital infections product.
3. lactobacillus curvatus according to claim 1 or its tunning or its bacteria suspension or its nutrient solution are preparing the application in antimicrobial product.
4. application according to claim 3, is characterized in that: described bacterium is bacterium, and described bacterium is specially streptococcus aureus.
5. lactobacillus curvatus according to claim 1 or its tunning or its bacteria suspension or its nutrient solution adhere to the application in vaginal epithelial cell product in preparation.
6. prevent and/or treat a urogenital infections product, its activeconstituents is lactobacillus curvatus according to claim 1 or its tunning or its bacteria suspension or its nutrient solution.
7. an antimicrobial product, its activeconstituents is lactobacillus curvatus according to claim 1 or its tunning or its bacteria suspension or its nutrient solution.
8. product according to claim 7, is characterized in that: described bacterium is bacterium, and described bacterium is specially streptococcus aureus.
9. adhere to a vaginal epithelial cell product, its activeconstituents is lactobacillus curvatus according to claim 1 or its tunning or its bacteria suspension or its nutrient solution.
10., according to arbitrary described product in described application arbitrary in claim 2-5 or claim 6-9, it is characterized in that: described product is medicine or microbial inoculum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510954618.6A CN105349474B (en) | 2015-12-17 | 2015-12-17 | For preventing and treating the lactobacillus curvatus of women's urogenital infections |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510954618.6A CN105349474B (en) | 2015-12-17 | 2015-12-17 | For preventing and treating the lactobacillus curvatus of women's urogenital infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105349474A true CN105349474A (en) | 2016-02-24 |
| CN105349474B CN105349474B (en) | 2019-07-02 |
Family
ID=55325539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510954618.6A Active CN105349474B (en) | 2015-12-17 | 2015-12-17 | For preventing and treating the lactobacillus curvatus of women's urogenital infections |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105349474B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107937324A (en) * | 2018-01-10 | 2018-04-20 | 中国科学院微生物研究所 | One plant of Lactobacillus crispatus and its application |
| WO2022100631A1 (en) * | 2020-11-10 | 2022-05-19 | 深圳华大生命科学研究院 | Lactobacillus crispatus for preventing and/or treating genital tract flora disorder related diseases |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104232537A (en) * | 2014-09-03 | 2014-12-24 | 中国科学院微生物研究所 | Lactobacillus crispatus and application thereof |
| CN104630083A (en) * | 2013-11-08 | 2015-05-20 | 苏州欧赛微科生物医药科技有限公司 | Lactobacillus crispatus and applications thereof in woman healthcare products |
| CN104673702A (en) * | 2014-11-21 | 2015-06-03 | 北京百益恒源科技有限公司 | Lactobacillus curvatus and pharmaceutical application thereof |
-
2015
- 2015-12-17 CN CN201510954618.6A patent/CN105349474B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104630083A (en) * | 2013-11-08 | 2015-05-20 | 苏州欧赛微科生物医药科技有限公司 | Lactobacillus crispatus and applications thereof in woman healthcare products |
| CN104232537A (en) * | 2014-09-03 | 2014-12-24 | 中国科学院微生物研究所 | Lactobacillus crispatus and application thereof |
| CN104673702A (en) * | 2014-11-21 | 2015-06-03 | 北京百益恒源科技有限公司 | Lactobacillus curvatus and pharmaceutical application thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107937324A (en) * | 2018-01-10 | 2018-04-20 | 中国科学院微生物研究所 | One plant of Lactobacillus crispatus and its application |
| CN107937324B (en) * | 2018-01-10 | 2020-01-21 | 中国科学院微生物研究所 | Lactobacillus crispatus and application thereof |
| WO2022100631A1 (en) * | 2020-11-10 | 2022-05-19 | 深圳华大生命科学研究院 | Lactobacillus crispatus for preventing and/or treating genital tract flora disorder related diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105349474B (en) | 2019-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101974450B (en) | Leuconostoc mesenteroides and application thereof | |
| CN111534446B (en) | Lactobacillus reuteri and application thereof | |
| CN1888051B (en) | Plant lactobacillus strain and its application | |
| CN102851248B (en) | Lactobacillus jensenii for preventing and curing bacterial vaginosis | |
| CN104630083A (en) | Lactobacillus crispatus and applications thereof in woman healthcare products | |
| CN107794236A (en) | A kind of Lactobacillus crispatus and its application | |
| CN101974449A (en) | Lactobacillus plantarum and application thereof | |
| CN103275893A (en) | Complex microbial inoculants of bifidobacterium longum and bifidobacterium animalis and preparation method of complex microbial inoculants | |
| CN103911306B (en) | Lactobacillus gasseri bacterial strain and application thereof | |
| CN103409334A (en) | Lactobacillus for inhibiting pathogenic bacteria of vaginitis and application thereof | |
| CN103911305B (en) | Lactobacillus crispatus bacterial strain and uses thereof | |
| CN103074270A (en) | Lactobacillus crispatus and application | |
| CN104232537B (en) | Lactobacillus crispatus and application thereof | |
| CN112725219A (en) | Bifidobacterium adolescentis strain and application thereof | |
| CN103039710B (en) | Method for producing camellia oil cake feed through mixed strain fermentation | |
| CN103343107A (en) | Human lactobacillus casei gr x 12 with antioxidant function and application thereof | |
| CN102008110B (en) | Multi-strain microbial composite beverage preparation and preparation method thereof | |
| CN108542954A (en) | A kind of Traditional Chinese medicine gel composition of inhibitory anti-virus | |
| CN103911309B (en) | Lactobacillus gasseri bacterial strain and application thereof | |
| CN104673702B (en) | One plant of lactobacillus curvatus（Lactobacillus crispatus）And its pharmaceutical applications | |
| CN101935628A (en) | Bacillus subtilis and application thereof | |
| CN105349474A (en) | Lactobacillus.crispatus for preventing female urogenital tract infection | |
| CN104293718B (en) | Lactobacillus jensenii and application thereof | |
| CN103911307B (en) | Lactobacillus crispatus bacterial strain and uses thereof | |
| CN103555604B (en) | Lactobacillus salivarius capable of inhibiting Candida albicans growth, and separation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |